Skip to content

Focused fMRI and Brainstem Evoked Response Audiometry (BERA) to Probe the Brainstem Mechanism in Tinnitus

Focused fMRI and Brainstem Evoked Response Audiometry (BERA) to Probe the Brainstem Mechanism in Tinnitus - Focused fMRI and BERA for tinnitus

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON48145
Enrollment
90
Registered
2019-08-12
Start date
2020-03-10
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ringing in the ears

Interventions

None listed

Sponsors

Keel-, Neus- en Oorheelkunde
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: To be eligible to participate in this study, the subject - must be in the age range of 18-80 years old. - must have a hearing threshold of both ears between 40 dB and 60 dB, if he/she is in one of the bilateral hearing loss groups. - must have a hearing threshold between 40 dB and 60 dB for one ear, and the normal hearing threshold, less than 20 dB, for the other ear, if he/she is in one of the unilateral hearing loss groups. - must have a hearing threshold of less than 20 dB for both ears, if he/she is in one of the normal threshold groups.

Exclusion criteria

Exclusion criteria: - Non-conformance to any of the inclusion criteria. - Contraindication for MRI according to the MRI checklist. - Reported medical, neurological, or psychiatric disorders (excluding tinnitus and hearing loss).

Design outcomes

Primary

MeasureTime frame
The main endpoints are differences between response characteristics associated with hearing loss laterality and the presence of tinnitus. These differences include the difference in the response amplitudes of various brainstem nuclei as assessed by fMRI, BERA and, tonotopic maps as assessed by MRI.

Secondary

MeasureTime frame
n.v.t

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)